These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20232719)

  • 41. Acute Laryngeal Dystonia Associated With Asenapine Use: A Case Report.
    Collins N; Sager J
    J Clin Psychopharmacol; 2017 Dec; 37(6):738-739. PubMed ID: 29040152
    [No Abstract]   [Full Text] [Related]  

  • 42. Lumateperone (Caplyta) for bipolar depression.
    Med Lett Drugs Ther; 2022 Aug; 64(1656):126-128. PubMed ID: 35921078
    [No Abstract]   [Full Text] [Related]  

  • 43. [Asenapine in bipolar disorder: efficacy, safety and place in clinical practice].
    Samalin L; Tixeront C; Llorca PM
    Encephale; 2012 Jun; 38(3):257-65. PubMed ID: 22726414
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: meta-analyses of randomized-controlled trials.
    Vita A; De Peri L; Siracusano A; Sacchetti E;
    Int Clin Psychopharmacol; 2013 Sep; 28(5):219-27. PubMed ID: 23719049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. QTc Prolongation and Ventricular Trigemini with Asenapine: A Case Report.
    Gıll JS; Sulaıman AH
    Turk Psikiyatri Derg; 2018; 29(1):67-68. PubMed ID: 29730876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
    Szegedi A; Calabrese JR; Stet L; Mackle M; Zhao J; Panagides J;
    J Clin Psychopharmacol; 2012 Feb; 32(1):46-55. PubMed ID: 22198448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
    Augusto M; Greene M; Touya M; Sweeney SM; Waters H
    J Comp Eff Res; 2018 Jul; 7(7):627-636. PubMed ID: 29694243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.
    Kemp DE; Zhao J; Cazorla P; Landbloom RP; Mackle M; Snow-Adami L; Szegedi A
    J Clin Psychiatry; 2014 Mar; 75(3):238-45. PubMed ID: 24499969
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.
    Sawyer L; Azorin JM; Chang S; Rinciog C; Guiraud-Diawara A; Marre C; Hansen K
    J Med Econ; 2014 Jul; 17(7):508-19. PubMed ID: 24720805
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.
    Alphs L; Panagides J; Lancaster S
    Psychopharmacol Bull; 2007; 40(2):41-53. PubMed ID: 17514185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Asenapine: a less effective, yet, more dangerous neuroleptic!
    Prescrire Int; 2012 Oct; 21(131):229-32. PubMed ID: 23185842
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
    Bobo WV
    Expert Rev Clin Pharmacol; 2013 Jan; 6(1):61-91. PubMed ID: 23272794
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder.
    Findling RL; Landbloom RL; Szegedi A; Koppenhaver J; Braat S; Zhu Q; Mackle M; Chang K; Mathews M
    J Am Acad Child Adolesc Psychiatry; 2015 Dec; 54(12):1032-41. PubMed ID: 26598478
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.
    Berk M; Tiller JW; Zhao J; Yatham LN; Malhi GS; Weiller E
    J Clin Psychiatry; 2015 Jun; 76(6):728-34. PubMed ID: 25612216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.
    McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
    J Affect Disord; 2010 Nov; 126(3):358-65. PubMed ID: 20537396
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Asenapine for the treatment of stuttering: an analysis of three cases.
    Maguire GA; Franklin DL; Kirsten J
    Am J Psychiatry; 2011 Jun; 168(6):651-2. PubMed ID: 21642484
    [No Abstract]   [Full Text] [Related]  

  • 57. An update on the treatment of mixed bipolar states: what is new in 2013?
    Ouanes S; Chennoufi L; Cheour M
    J Affect Disord; 2014 Apr; 158():53-5. PubMed ID: 24655765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ziprasidone, a new atypical antipsychotic drug.
    Carnahan RM; Lund BC; Perry PJ
    Pharmacotherapy; 2001 Jun; 21(6):717-30. PubMed ID: 11401184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of asenapine in clinical practice for the management of bipolar mania.
    Young AH; Altamura AC; González-Pinto AM; Millet B; Wiedemann K
    J Psychopharmacol; 2013 Apr; 27(4 Suppl):3-13. PubMed ID: 23535350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
    J Affect Disord; 2010 Apr; 122(1-2):27-38. PubMed ID: 20096936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.